Swiss biotechnology company Molecular Partners AG reported on Tuesday that its current cash reserves will extend through late 2027 under existing spending plans, with potential partnership payments excluded. The company, which generates no revenue, highlighted its financial runway as a key metric for investors given its pre-commercial stage of development.
Operating costs for the first half of 2026 totaled 27 million Swiss francs, down from 37.2 million francs in the same period last year. Research and development expenses declined to 19 million francs from 22.6 million francs, contributing to a narrowed net loss of 26.7 million francs compared with a 37.2 million franc deficit in H1 2025. Molecular Partners maintained its full-year 2026 operating cost guidance of 45 million to 55 million Swiss francs.
The company’s lead asset, MP0712, targets small-cell lung cancer and other neuroendocrine tumors by binding to the DLL3 protein on cancer cells and delivering targeted alpha radiation via the isotope lead-212. Developed in collaboration with Orano Med, MP0712 is progressing through a Phase I clinical trial. The initial dose cohort of 75 megabecquerels per treatment has been fully enrolled, with some patients receiving up to four doses. Reported adverse events have been mild to moderate and transient, according to Chief Executive Patrick Amstutz, who noted no dose-limiting toxicities.
Following these results, Molecular Partners initiated the next dose level at 105 megabecquerels per treatment. Four dose escalation stages are planned, with preliminary clinical data expected in 2026 and more comprehensive safety and efficacy data slated for 2027. The company is also advancing a second Radio-DARPin program, MP0726, targeting mesothelin, with first-in-human imaging studies scheduled for the second half of 2026. A third program, MP0714, is already being administered under an early access protocol in South Africa using alternative radioisotopes.
Molecular Partners has expanded its Radio-DARPin pipeline to include CD70, a target associated with certain kidney cancers. Preclinical data for this program are expected in 2026, with a clinical trial launch planned for 2027.
